Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

PepsiCo to Reduce Sugar in Over 60 Percent of Soft Drinks

XTALKS VITALS NEWS

Beverage

The move is part of the company’s plans to address the growing obesity epidemic.

Tweetables from this article:

Tweet: Pepsico to reformulate at least 2/3 of soft drinks by 2025 to be 100 calories or less http://ctt.ec/z23_3+ Pepsico to reformulate at least 2/3 of soft drinks by 2025 to be 100 calories or less.

Share this!

October 18, 2016 | by Sarah Hand, M.Sc.

PepsiCo has announced its plan to globally reduce the amount of sugar in its range of soft drinks. The move is part of the company’s plans to address the growing obesity epidemic.

Its target is to reformulate at least two thirds of its soft drinks by 2025, so that they have less than 100 calories from added sugar per 12 oz. can. Approximately 40 percent of PepsiCo’s drinks already meet those requirements.

PepsiCo and Coca-Cola have faced increased scrutiny from governments and nutrition experts who say high-sugar drinks have contributed to the increased rates of obesity and diabetes in the US. The company plans to meet its target both by reformulating existing products, and launching new zero and low-calorie beverages.



According to Mehmood Khan, PepsiCo's chief scientific officer of research and development, this new target is an improvement over their previous goal of removing 25 percent of sugars in select drinks and markets by 2020. “The science has evolved,” Khan told Reuters. “It's not just about sweeteners, it's about understanding the flavor ingredients and having proprietary knowledge and access to them.”

Earlier this month, the World Health Organization (WHO) recommended that countries should start imposing a sugar tax on sweet soft drinks. While this system has already been implemented in France and Mexico in an attempt to limit consumption of the beverages, PepsiCo is in strong opposition to the tax.

PepsiCo’s nutritional goals also include reducing sodium and saturated fats in some of its snack products, by 2025. About 12 percent of the company’s $63 billion in annual revenue comes from sales of its namesake drink, Pepsi, but the bulk of their profits come from other soft drinks, along with bottled water, juices, snacks and dips.

“These are good steps. But when we have an obesity crisis, I think there is more that we can be doing,” said Mindy Lubber, president of Ceres, a non-profit organization focused on sustainability in industry. “If a food and beverage company is not looking at nutrition, they are not looking at the direction the world is going in.”


Keywords: Beverage, Obesity, Diabetes


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Use of Testosterone Treatments Boosted by DTC Ad Campaigns

March 24, 2017 - Those with a stake in the pharmaceutical industry often question the effectiveness of direct-to-consumer (DTC) advertising, and whether it truly influences consumers to talk to their doctors about medical conditions and perhaps even ask for drugs by name.

Featured In: Pharmaceutical Marketing News


FDA Approves New Drug for Parkinson’s Disease

March 23, 2017 - Newron Pharmaceuticals’ Xadago (safinamide) has been approved by the US Food and Drug Administration (FDA) as an add-on medication for patients with Parkinson’s disease.

Featured In: Clinical Trials News, Life Science News, Pharmaceutical News


Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.